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1. Introduction 
We have been forced to fight against the newly acquired antibiotic resistance of various 
bacteria. By the end of the 1970s, most Escherichia coli (E. coli) and Klebsiella pneumoniae (K. 
pneumoniae) strains contained plasmid-mediated, ampicillin-hydrolyzing -lactamases, such 
as TEM-1, TEM-2, and SHV-1, and could be eliminated by the use of third-generation 
cephalosporins. 1 TEM-1 and TEM-2 were detected mainly in E. coli, and SHV-1 was mainly 
detected in K. pneumoniae. 2 The emergence of K. pneumoniae strains with a gene encoding -
lactamase that hydrolyzes the extended-spectrum cephalosporins was first reported by a 
study from Germany in 1983. 3 The gene encoding the new -lactamase harbored a single-
nucleotide mutation, as compared to the parental blaSHV-1 gene. In 1986, K. pneumoniae 
strains resistant to the third-generation cephalosporins were detected in France. 4 The 
resistance was attributed to a new -lactamase gene, which was closely related to TEM-1 
and TEM-2. These newly detected -lactamases capable of hydrolyzing extended-spectrum 
-lactam antibiotics were named extended-spectrum -lactamases (ESBLs). 5 In 1989, the 
CTX-M type was reported as a new ESBL family member not belonging to either the TEM or 
SHV types. 6 Notably, the origin of CTX-M ESBLs is totally different from that of TEM or 
SHV ESBL. 7 Until the end of the 1990s, most of the ESBLs detected were either the TEM or 
SHV types and were usually associated with nosocomial outbreaks caused by K. pneumoniae. 
1 In the new millennium, the worldwide spread of CTX-M-producing E. coli has been 
dramatic, and they are now considered to be the primary ESBL producers that are almost 
always associated with community-acquired infections. 8 ESBL-producing E.coli and 
Klebsiella spp. are now listed as one of the six drug-resistant pathogens for which few 
potentially effective drugs are available. 9 This chapter will outline the genetic aspects of 
TEM, SHV, and CTX-M ESBLs, including molecular epidemiology and mobile elements. In 
addition, we will also consider the impact of their genetic evolution on clinical aspects, 
including mode of infection and antibiotic resistance. 
2. ESBL definition/classification 
There is no exact definition of ESBLs. ESBLs are generally defined as -lactamases that 
confer resistance to bacteria against the penicillins, the first-, second-, and third-generation 
cephalosporins, and to aztreonam by hydrolyzing these antibiotics, and are inhibited by -
lactamase inhibitors. 1 Most of ESBLs are classified as class A on the basis of the scheme 
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devised by Ambler et al. 10 Class A ESBLs form a heterogeneous molecular group, which 
comprises -lactamases sharing various identities, and consists of three major groups: the 
TEM, SHV, and CTX-M types. 7 TEM and SHV ESBLs genetically evolved from TEM-1, 
TEM-2, and SHV-1 progenitors (non-ESBLs), and CTX-M ESBLs developed independently 
from TEM and SHV ESBLs. Additional ESBL types, such as PER, VEB, and BES, are 
uncommon. 10 More than 130 TEM types and more than 50 SHV types are currently known. 
10 The most common group of ESBLs not belonging to the TEM or SHV types is CTX-M, the 
name derives from the potent hydrolytic activity against cefotaxime. 1 More than 40 CTX-M 
types are now recognized and can be divided into five subgroups, CTX-M1, 2, 8, 9, and 25, 
according to their amino acid sequence similarities. 7 
3. Global epidemiology: dissemination of ESBLs 
ESBLs were first detected in the first half of the 1980s in Europe, and they later disseminated 
worldwide. 1 Until the 1990s, the main producer of ESBLs was K. pneumoniae and 
nosocomial outbreaks caused by the organism were often reported. 1 The number of ESBL-
producing E. coli isolates has been dramatically increasing during the 21st century. 11 A 
recent global surveillance database collected from Europe, North and South America, and 
Asia, showed that the detection frequencies for ESBL-producing K. pneumoniae and E. coli 
isolates were 7.5-44% and 2.2-13.5%, respectively. 12 The prevalence of ESBL-producing 
isolates increased to a greater degree, particularly in Asia than in other regions, and one 
study conducted in 2007 showed that the frequencies of ESBL-producing K. pneumoniae and 
E. coli isolates exceeded 30% in both bacterial populations. 13 A recent surveillance using 
samples collected from nine Asian countries showed ESBL producers accounted for 42.2% of 
K. pneumoniae isolates detected from patients with hospital-acquired pneumoniae. 14 Our 
data collected from one institution in Japan showed that the detection rate of the E. coli 
isolates increased first, followed by increased detection rates of the K. pneumoniae and P. 
mirabilis isolates. 15 (Figure1) These data suggest that K. pneumoniae, as well as E. coli, has 
been an important ESBL producer even in the last few years. 
In the analysis of ESBL genotypes, TEM and SHV were predominantly observed until the 
1990s, and it was most reported that SHV-producing K. pneumoniae strains showed clonal 
dissemination in hospitals. 1 Recent studies show that TEM and SHV types have been 
frequently detected up to the present day. Interestingly, in some cases, SHV has been found 
in isolates expressing other ESBL types, such as TEM and CTX-M. 16 Our study showed that 
multiple types of ESBLs, including TEM, SHV, and CTX-M, were most frequently detected 
in K. pneumoniae and E. coli. 15 (Table1) These findings suggest that the genetic mechanism 
underlying dissemination of ESBL genes has become more divergent and complicated. After 
the first half of the 2000s, it was often reported that the number of CTX-M ESBLs detected 
was on the rise, that the main carrier was E. coli, and that most of the CTX-M-producing E. 
coli strains were acquired in the community, not in hospitals. 11 The detection rate of CTX-M 
ESBLs has been dramatically rising, especially in the last 5 years. 17 The mechanism behind 
the spread of blaCTX-M genes differs from that observed in the case of blaTEM and blaSHV 
genes. blaTEM and blaSHV ESBL genes are associated with the dissemination of particular 
clones, known as an “epidemic” pattern; however, the mechanism by which blaCTX-M ESBL 
genes disseminate reflects the simultaneous spread of multiple specific clones, known as an 
“allodemic” pattern. 18 It has been indicated that various CTX-M-type ESBLs have spread 
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Fig. 1. Frequencies of ESBL-producing organisms at Hara-Sanshin Hospital in Fukuoka (Japan) 
worldwide, and that specific CTX-M subgroups have been characterized in different 
geographic areas. 15,18,19 In contrast, CTX-M-15 ESBLs, which belong to the CTX-M-1 group, 
have been found worldwide. 18 Unlike in other countries, in the USA, ESBLs were rarely 
detected, until the first half of the 2000s; however, CTX-M ESBLs, specifically CTX-M-15, 
have frequently been encountered over the last 5 years. 20,21 
 
 
Table 1. Genotypes of ESBL-producing Eschrichia coli isolated from hospitalized patients 
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4. Genetic characteristics 
Genes harboring ESBLs are associated with several specific genetic structures. A variety of 
mobile genetic elements, such as transposons, insertion sequences, and integrons, play 
important roles in the dissemination of ESBL genes. blaTEM-type ESBL genes are acquired 
by the mutation of plasmid-mediated, parent blaTEM-1 and blaTEM-2 genes, and the main 
producer of TEM-type ESBLs is E. coli; these genes occur within the earliest bacterial 
transposons identified. 2,22 blaSHV-type ESBL genes are the derivatives of chromosomal, 
parent blaSHV-1 genes, which occur mainly in K. pneumoniae,23 and are likely acquired by 
the role of insertion sequences from chromosome to plasmid. 22 Notably, blaTEM-type and 
blaSHV-type ESBL genes located in the integron structures have never been identified. 22 The 
spread of blaCTX-M-type ESBL genes is associated with more complicated mobile elements, 
compared to that of blaTEM and blaSHV ESBL genes. blaCTX-M ESBL genes are not 
derivatives of K. pneumoniae or E. coli that contain original genes, as compared to blaTEM or 
blaSHV ESBL genes. blaCTX-M genes originate from the chromosomal -lactamase genes of 
Kluyvera species, which are environmental bacteria found worldwide, and are captured mainly 
by insertion sequence elements translocated from chromosome to plasmid. 18 Original -
lactamase genes of Kluyvera species are identified in most CTX-M subgroups. 18 This 
differential origin might be involved in the characteristic spread of blaCTX-M ESBL genes, that 
is, an “allodemic” pattern of spread. All blaCTX-M genes are associated with insertion 
sequences. Well-studied, CTX-M-associated insertion sequence elements include ISEcp1 and 
ISCR1, which are involved in the mobilization of blaCTX-M genes by a transposition 
mechanism. 24,25,26 In addition, integron structures bearing insertion sequences and blaCTX-M 
genes can be linked to transposon elements, such as from the Tn21 family, which has been 
intensively studied. Transposons of the Tn21 family are disseminated worldwide in both 
environmental and clinical bacteria.18,24 These highly efficient mobile genetic elements may 
have influenced the rapid and easy dissemination of blaCTX-M ESBL genes. 
An antibiotic resistance plasmid itself is responsible for the efficiency of gene transfer, as 
well as the mobile genetic elements described above. It has been shown that ESBL gene-
bearing plasmids can be transferred to different bacterial species by conjugation. 27,28 
Previous studies have shown that blaTEM and blaSHV ESBL genes are associated with 
plasmids belonging to a few specific incompatibility (Inc) groups.18 In contrast, blaCTX-M 
ESBL genes are carried by plasmids belonging to a variety of Inc groups including narrow- 
and broad-host-range types. 18,29 blaCTX-M-15 genes are located mainly on plasmids belonging 
to the IncF group. 29 Interestingly, a recent study has described the diversity of ESBL gene-
bearing plasmids, including SHV types. 30 It was reported that a mosaic plasmid has been 
identified from a clonal CTX-M-producing E. coli isolate, suggesting genetic interactions 
among different plasmids. 31 In ESBL gene-bearing plasmids, the genetic diversity has been 
constantly increasing through the mechanism of gene transfer and gene shuffling. 
5. Clinical impact 
5.1 The mode of infection 
5.1.1 Nosocomial infection 
Up to the end of the 1990s, clinical infections caused by ESBL-producing bacteria were 
associated with nosocomial outbreaks, where the chief ESBL producer was K. pneumoniae, 
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but not E. coli. In addition, the ESBL genotypes detected in the nosocomial setting were 
almost always TEM and SHV, but not CTX-M types. 1 SHV-producing K. pneumoniae strains 
were intensively examined in the analysis of clonal dissemination in hospitals. Clonally 
related SHV-4-producing K. pneumoniae isolates were shown to have spread to multiple 
hospitals within the specific region. 32 This phenomenon indicates that, at that time, the 
mode of spread for SHV-producing K. pneumoniae was the dissemination of particular 
clones, that is to say, an “epidemic” pattern. The number of nosocomial outbreaks caused by 
TEM- or SHV-producing K. pneumoniae strains have been decreased during this century; 
however, as observed in many studies, these organisms are frequently identified in many 
hospitals worldwide. Interestingly, the derivatives of TEM and SHV types have been 
reported to be more divergent in K. pneumoniae strains isolated in European hospitals. 16,33 
Moreover, the new variants of blaSHV genes were detected from an Algerian hospital. 34 
5.1.2 Community-acquired infection 
The mode of ESBL-related infection has dramatically changed since the 2000s. Community-
acquired infections caused by ESBL-producing bacteria have been increasingly documented. 
8 CTX-M-producing E. coli strains are chiefly responsible for community-acquired 
infections, which are related to an increase in the number of ESBL carriers in the general 
population. 11,35 One report describes a significant increase in the prevalence of ESBL carriers 
in a specific population from 2001 to 2006. 36 The interfamilial dissemination of ESBL-
producing bacteria has also been suggested. 37 Notably, animals used as food and or pets are 
reported to carry CTX-M ESBLs, 38,39,40,41 and this finding may explain the dramatic spread of 
ESBLs in the community. The community-onset dissemination of ESBLs in both humans and 
animals may suggest that blaCTX-M ESBL genes detected in pathogenic bacteria are 
acquired from environmental bacteria. Branger et al showed that many CTX-M ESBLs were 
associated with the phylogenetic group D2 that lacked a virulence factor. 42, 43 The specific 
features may be related to the colonization and spread among the general population. The 
spread of ESBLs in the community is linked to the emergence of ESBL-related infections in 
outpatients, in whom urinary tract infections are most often reported along with bacteremia. 
44,45, 46 One study has described the detection of CTX-M-producing K. pneumoniae in 
outpatients, 33 A nosocomial outbreak was caused by CTX-M-producing K. pneumoniae 
isolates from foods, suggesting the influx of ESBL-producing K. pneumoniae into a hospital. 47 
These reports may account for the dissemination of CTX-M ESBL genes from E. coli to other 
bacteria in the community. 
5.2 Antibiotic resistance 
Antibiotic resistance is of utmost importance for the clinical impact of ESBL-producing 
bacteria. A meta-analysis showed increased mortality and delay in effective antibiotic use in 
ESBL-related bacteremia, 48 indicating the importance of constant surveillance for an 
antibiotic resistance pattern in organisms with ESBLs. ESBL-producing bacteria are resistant 
to almost all -lactam antibiotics, except carbapenems, as indicated by their definition. In 
addition, most ESBL-producing bacteria, particularly those with the TEM, SHV, and CTX-M 
genotypes, exhibit co-resistance to aminoglycosides, tetracyclines, and sulfonamides. 18 
Organisms with CTX-M genotypes, such as those with CTX-M-9, -14, and -15, are reported 
to be resistant to fluoroquinolones. 18 This additional resistance is induced by the main 
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mechanism that blaCTX-M genes are directly linked to quinolone resistance genes, qnr 
genes. ISCR1, a mobile element for blaCTX-M genes, is associated with qnr genes, 26 
indicating an effective transfer of quinolone resistance genes together with blaCTX-M genes. 
This genetic finding is interesting for clinical reasons. Selective pressure by the use of 
fluoroquinolones may induce the emergence of CTX-M ESBL-producing bacteria. As a 
consequence, the therapeutic options for infections caused by ESBL-producing bacteria may 
be more limited. Tigecycline has been shown to be microbiologically active against ESBL-
producing E. coli and K. pneumoniae, 49,50 whereas, fosfomycin has been reported to be 
effective against urinary tract infections caused by ESBL-producing E. coli. 51,52 
6. Spread of CTX-M-15-producing ST131 E. coli clones 
The dissemination of CTX-M-15 producing E. coli strains has become a major concern of 
research in antibiotic resistance. The first isolation of CTX-M-15-type ESBLs was reported in 
India in 2001. 53 CTX-M-15 is derived from CTX-M-3, belonging to the CTX-M-1 group, 
differing by one amino acid substitution. blaCTX-M-15 genes are transferred mainly by the 
IncF group plasmids, which are well adapted to E. coli and have acquired many antibiotic 
resistance genes. 54,55,56 Recently, Mnif et al reported that the IncF plasmids carrying blaCTX-
M-15 genes contained many addiction systems, which could contribute to their maintenance 
in E. coli host strains. 57 The detection rate of the CTX-M-15 producing E. coli strains with 
multidrug resistance has been dramatically increasing worldwide since the 2000s. 56 This 
CTX-M-15-producing E. coli strain is often thought to be associated with ST131 clones. 56 
Most of the CTX-M-15-producing E. coli strains isolated from three continents were O25:H4-
ST131 clones that show highly similar PFGE profiles, suggesting a recent emergence of these 
clones. 58 The emergence of the CTX-M-15-producing ST131 E. coli clones is highly related to 
the recent dissemination of ESBLs in the USA. 59, 60 The worldwide spread of the multi-drug-
resistant ST131 E. coli clones can be explained by the acquisition of IncFII plasmids 
harboring blaCTX-M-15 genes and many other antibiotic resistance genes. Interestingly, 
these ST131 E. coli clones belong to the highly virulent, phylogenetic group B2. 56 Over the 
past 5 years, CTX-M-15-producing ST131 E. coli clones have become an important causative 
agent for community-acquired ESBL infections, mainly urinary tract infections and 
bacteremia. 45 
7. Clinical impact on immunodeficient patients 
The sufficient therapy for ESBL-related infections is important, especially in 
immunodeficient patients. One study has shown that approximately 13% of E. coli-related 
bacteremia cases detected in patients with cancer and neutropenia were caused by ESBLs, 
that CTX-M types were predominant among the ESBLs, and that the bacteremia induced by 
ESBL-producing E. coli strains was linked to inadequate empirical antibiotic therapy. 61 In 
our institution, the detection rate of ESBL-related bacteremia has been increasing in febrile 
neutropenic patients with hematological malignancies, and consequently, we have been 
forced to use carbapenems for the therapy. 62,63 In immunodeficient patients, such as those 
undergoing chemotherapy, serious ESBL-related infections may result in a poor prognosis 
owing to the failure of the initial therapy. Recently, M. D. Anderson Cancer Center has 
reported an interesting finding that pyomyositis was caused by ESBL-producing E. coli 
strains in neutropenic patients with hematological malignancies, and that the E. coli strains 
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were ST131 clones belonging to phylogenetic group B2. 64 This notable finding implies that 
ESBL-producing ST131 E. coli clones cause fatal damage in the case of immunodeficient 
patients because of their high virulence. 
8. Conclusions 
The spread of ESBL-producing bacteria in the community has begun influencing outpatient 
therapy. Community-acquired bacteremia, due to ESBL-producing E. coli strains, is 
becoming a critical concern for outpatients, because inappropriate use of empirical 
antibiotics, such as cephalosporins and fluoroquinolones, has resulted in high mortality. 65,66 
One study has shown that the resistance of CTX-M-15-producing ST131 E. coli strains 
isolated from the community to fosfomycin has increased. 67 In the near future, we may be 
forced to use carbapenems as the first choice for the empirical therapy of patients with 
community-acquired infections due to ESBL-producing bacteria. The identification of 
carbapenemase-producing E coli and K. pneumoniae strains has been frequently documented 
as evidence for additional -lactamases-producing bacteria other than the ESBL-producing 
bacteria. 68 The study of NDM-1-type carbapenemase-producing E coli and K. pneumoniae is 
currently a topic of much interest in multidrug-resistant bacteria research. Notably, some of 
the NDM-1-type-producing E coli and K. pneumoniae strains express blaCTX-M-15 ESBL 
genes in a single isolate. 69,70,71 A worldwide surveillance recently showed that many NDM-
1-producing bacteria detected carried additional ESBL genes. 72 The acquisition of efficient 
mobile elements has accelerated the transfer of various antibiotic resistance genes. 
Potentially, a “super bug,” resistant to almost all licensed antibiotics, may emerge in the 
future. Constant and careful worldwide surveillance for multidrug-resistant bacteria is 
urgently warranted. 
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